Chip stocks rebound, and Goldman racks up a series of M&A wins

The S&P 500 and Nasdaq are on pace to end a five-session losing streak, with megacaps like Amazon, Alphabet and Meta leading a rebound while Corning and Palo Alto Networks hit new all-time highs. Goldman Sachs continues to benefit from M&A advisory work on deals including Martin Marietta's $13.5B acquisition of Lhoist North America and Bio-Techne's $11.3B sale of Merck KGaA, while Wells Fargo is seeing traction in investment banking despite a roughly 10% YTD decline. Upcoming catalysts include Wells Fargo, Goldman Sachs and other large banks reporting in two weeks, plus Thursday's nonfarm payrolls release.

Analysis

The key signal is not the broad index bounce; it is leadership rotation back toward high-beta growth, semis, and software security while defensives lag. That usually happens when the market is pricing a softer near-term macro path without fully abandoning earnings growth, which is constructive for names with operating leverage and recurring revenue. In that setup, large-cap defensives can continue to underperform even if the tape is green, because investors are rotating away from “safety” and into reflexive upside.

The most actionable second-order effect is in capital markets activity. Goldman’s pipeline strength suggests M&A and financing fees are not just surviving higher-for-longer rates; they are being normalized as boards accept current valuation and funding conditions. That matters because it broadens the earnings support beyond underwriting headlines: advisory, committed financing, and follow-on transactions can offset muted trading revenue, making the banks with real franchise breadth less sensitive to rate noise than the market assumes.

Healthcare’s new highs look more durable than a simple defensive bid. If the market is shifting from AI-only leadership to broader quality growth, large-cap healthcare can re-rate on its own fundamentals while staying relatively insulated from tariff and consumer cyclicality. By contrast, the weak response in staples and home/industrial-adjacent defensives signals that investors are not seeking shelter; they are expressing preference for visible growth, which can persist into the payroll print if labor data cools without breaking recessionary.

Near term, the main risk is a hot labor number or a stronger-than-expected confidence print that pushes rates higher and punishes the growth complex again. Longer term, the trap is extrapolating one session of breadth into a trend change: if the July bank earnings season disappoints on net interest income or guidance, the recent optimism in financials will fade quickly. The setup favors selective exposure, not broad beta, because the market is rewarding idiosyncratic execution more than macro purity right now.

Key Decisions for Investors

• Add to GOOGL/META vs. MSFT/AAPL on a 2-4 week horizon: long the names with stronger relative momentum and ad/engagement optionality, short the laggards as a pair trade; use a 3-5% stop on the spread if rate-sensitive growth rolls over.
• Increase GS exposure into Q2 earnings, but fund it by trimming weaker bank beta like WFC: GS has the cleaner fee-based catalyst path over the next 1-2 quarters, while WFC still carries execution risk if NII guidance is not revised up.
• Buy PANW or GLW on pullbacks only, not strength chasing: both have technical breakout characteristics, but the better risk/reward is a shallow retracement entry with a 6-8% downside stop and 12-15% upside over the next month.
• Fade staples defensives selectively via COST or PG relative to the Nasdaq over the next 2-3 weeks: if the market keeps rewarding growth, these names can remain dead money despite high quality; pair the short against QQQ to isolate style rotation.
• For healthcare, prefer JNJ or CAH as medium-duration longs into month-end: the trade is a quality-lag catch-up, with upside from continued new highs and lower drawdown risk than more cyclical sectors.